[1] V. M.-Y. Lee, “Biomedicine: tauists and βaptists united—well almost!,” Science, vol. 293, no. 5534, pp. 1446–1447, 2001.
[2] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
[3] A. Guntert, H. Dobeli, and B. Bohrmann, “High sensitiv- ity analysis of amyloid-β peptide composition in amyloid deposits from human and PS2APP mouse brain,” Neuroscience, vol. 143, no. 2, pp. 461–475, 2006.
[4] Y.-M. Kuo, M. R. Emmerling, C. Vigo-Pelfrey, et al., “Water- soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains,” Journal of Biological Chemistry, vol. 271, no. 8, pp. 4077–4081, 1996.
[5] J. W. Deitmer, “Strategies for metabolic exchange between glial cells and neurons,” Respiration Physiology, vol. 129, no. 1-2, pp. 71–81, 2001.
[6] W. Noske, H. Lentzen, K. Lange, and K. Keller, “Phagocytotic activity of glial cells in culture,” Experimental Cell Research, vol. 142, no. 2, pp. 437–445, 1982.
[7] H. Akiyama, S. Barger, S. Barnum, et al., “Inflammation and Alzheimer’s disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000.
[8] E. G. McGeer and P. L. McGeer, “Inflammatory processes in Alzheimer’s disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 5, pp. 741–749, 2003.
[9] C. F. Ide, J. L. Scripter, B. W. Coltman, R. S. Doston, D. C. Snyder, and A. Jelaso, “Cellular and molecular correlates to plasticity during recovery from injury in the developing mammalian brain,” Progress in Brain Research, vol. 108, pp. 365–377, 1996.
[10] S. Itagaki, P. L. McGeer, H. Akiyama, S. Zhu, and D. Selkoe, “Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease,” Journal of Neuroimmunology, vol. 24, no. 3, pp. 173–182, 1989.
[11] W. S. T. Griffin, L. C. Stanley, C. Ling, et al., “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 19, pp. 7611–7615, 1989.
[12] M. Huell, S. Strauss, B. Volk, M. Berger, and J. Bauer, “Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients,” Acta Neuropathologica, vol. 89, no. 6, pp. 544–551, 1995.
[13] D. Blum-Degena, T. Muller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer, “Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients,” Neuroscience Letters, vol. 202, no. 1-2, pp. 17–20, 1995.
[14] R. Cacabelos, M. Barquero, P. Garcia, X. A. Alvarez, and E. Varela de Seijas, “Cerebrospinal fluid interleukin-1β (IL-1β) in Alzheimer’s disease and neurological disorders,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 13, no. 7, pp. 455–458, 1991.
[15] D. M. Araujo and C. W. Cotman, “β-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in 
[16] E. N. Benveniste, V. T. Nguyen, and G. M. O’Keefe, “Immuno- logical aspects of microglia: relevance to Alzheimer’s disease,” Neurochemistry International, vol. 39, no. 5-6, pp. 381–391, 2001.
[17] P. Garcao, C. R. Oliveira, and P. Agostinho, “Comparative study of microglia activation induced by amyloid-β and prion peptides: role in neurodegeneration,” Journal of Neuroscience Research, vol. 84, no. 1, pp. 182–193, 2006.
[18] C. Lindberg, M.-L. B. Selenica, A. Westlind-Danielsson, and M. Schultzberg, “β-amyloid protein structure determines the nature of cytokine release from rat microglia,” Journal of Molecular Neuroscience, vol. 27, no. 1, pp. 1–12, 2005.